| abstract |
There is provided an antibody polypeptide that specifically binds to a novel epitope of human CD40. Such antibody polypeptides do not exhibit CD40 agonist activity. Such antibody polypeptides are useful in the treatment of diseases involving CD40 activation, such as autoimmune diseases. Such an antibody polypeptide may be a domain antibody (dAb) comprising a single V L or V H domain. The half life of an antibody polypeptide can be increased by modifying such antibody polypeptide to be a bispecific reagent capable of binding also to human serum albumin (HSA). |